THE CHILDREN’S BODIES ARE THE NEW EXPANDING MARKET FOR BIG PHARMA’S PROFITS: PRADAXA

Venous thromboembolism is a Covid19 injection adverse reaction. They were ready with this in June 2021. All perfectly timed to expand the pharmaceutical market into the children’s bodies.

The children’s bodies are just a market. This is what unbridled capitalism and the erasure of the soul lead to.

Robin Monotti

“The U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days.

The FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.

In addition, Pradaxa was approved in capsule form to treat blood clots in patients eight years and older with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days, and to prevent recurrent clots in patients eight years and older who completed treatment for their first venous thromboembolism.

Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth; the only other approved blood thinning medication for children is given by injection.”

FDA Approves First Oral Blood Thinning Medication for Children | FDA June 201
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-blood-thinning-medication-children